Clinical trial • Phase II | Phase IV • Psychiatry
Estradiol for Postpartum depression | Perinatal depression
Phase II | Phase IV trial of Estradiol for Postpartum depression | Perinatal depression. Placebo (Comfeel Plus Transparent from Coloplast).-controlled.
Overview
- Trial Therapeutic Area
- Psychiatry
- Trial Disease
- Postpartum depression | Perinatal depression
- Trial Stage
- Phase II | Phase IV
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 26-09-2024
- First CTIS Authorization Date
- 08-10-2024
Trial design
Placebo (Comfeel Plus Transparent from Coloplast).-controlled Phase II | Phase IV trial across 4 sites in Denmark.
- Comparator
- Placebo (Comfeel Plus Transparent from Coloplast).
- Target Sample Size
- 220
- Trial Duration For Participant
- 180
Eligibility
Recruits 220 Vulnerable population flag selected. Trial population consists of pregnant/postpartum adult women (aged 18-45). No detailed consent/assent handling information is provided in the available source documents..
- Pregnancy Exclusion
- Pregnancy-related hypertension or preeclampsia.
- Vulnerable Population
- Vulnerable population flag selected. Trial population consists of pregnant/postpartum adult women (aged 18-45). No detailed consent/assent handling information is provided in the available source documents.
Inclusion criteria
- {"criterion_text":"- Women between 18 and 45 years and pregnant in the third trimester."}
- {"criterion_text":"- Previously perinatal depression with the onset of depressive episode in pregnancy or within 6 months of birth or untreated depressive episode assessed by retrospective interview by healthcare professional."}
Exclusion criteria
- {"criterion_text":"- Antidepressant treatment by inclusion in the study."}
- {"criterion_text":"- Pregnancy-related hypertension or preeclampsia."}
- {"criterion_text":"- Manifest atherosclerosis or known cardiovascular risk factors (including diabetes, hypertension)."}
- {"criterion_text":"- Other contraindication for estrogen treatment (e.g. acute liver disease, varicicated varicencies)."}
- {"criterion_text":"- Use of psychotropic pharmacology, except for short-term sleep support treatment, which is likely to influence the results of the study."}
- {"criterion_text":"- Non-fluent in Danish or pronounced vision or hearing loss."}
- {"criterion_text":"- Current or previous learning difficulties."}
- {"criterion_text":"- BMI >35 kg/m2."}
- {"criterion_text":"- Current alcohol or drug abuse."}
- {"criterion_text":"- Multiple pregnancy."}
- {"criterion_text":"- Severe postpartum haemorrhage (>1500 ml)."}
- {"criterion_text":"- Moderate to severe depression developed in pregnancy before day 0 postpartum."}
- {"criterion_text":"- Serious illness or neonatal death in the child."}
- {"criterion_text":"- Severe mental illness, e.g. diseases of the schizophrenic spectrum, psychotic conditions, inpatient active eating disorder or hospitalising OCD, and bipolar affective disorder."}
- {"criterion_text":"- Previous suicide attempts outside the depressive episode."}
- {"criterion_text":"- Present or previous neurological disease including migraines and epilepsy."}
- {"criterion_text":"- Severe medical disease."}
- {"criterion_text":"- Past or ongoing cancer."}
- {"criterion_text":"- Previous venous thromboembolism, myocardial infarction, cerebrovascular thromboembolism or known thrombophilic diseases and risk factors clinically assessed after thrombophilic screening."}
- {"criterion_text":"- Deep vein thrombosis or pulmonary embolism in current pregnancy."}
Endpoints
Primary endpoints
- {"endpoint_text":"- Clinical depression according to DSM-V criteria. Between 2 weeks and 6 months postpartum","definition_or_measurement_approach":"Clinical diagnosis according to DSM-V criteria between 2 weeks and 6 months postpartum."}
Recruitment
- Planned Sample Size
- 220
- Recruitment Window Months
- 75
- Consent Approach
- Informed consent documents are listed (L2_ICF and L1_SIS) but their contents are not available in the provided source. Consent is from the adult participant (women aged 18-45). No details on assent, age-specific documents or languages available are provided in the source.
Geography
- Total Number Of Sites
- 4
- Total Number Of Participants
- 220
Denmark
- Earliest CTIS Part Ii Submission Date
- 11-09-2024
- Latest Decision Or Authorization Date
- 08-10-2024
- Processing Time Days
- 27
- Number Of Sites
- 4
- Number Of Participants
- 220
Sites
- Site Name
- Hvidovre Hospital
- Department Name
- Department of Obstetric and gynecology
- Contact Person Name
- Anette Kjaerbye-Thygesen
- Contact Person Email
- anette.kjaerbye-thygesen@regionh.dk
- Site Name
- Nordsjaellands Hospital
- Department Name
- Gynaekologisk-obstetrisk afdeling 0111
- Contact Person Name
- Ellen Loekkegaard
- Contact Person Email
- ellen.christine.leth.loekkegaard@regionh.dk
- Site Name
- Rigshospitalet
- Department Name
- Obstetrisk Afdeling
- Contact Person Name
- Kristina Martha Renault
- Contact Person Email
- kristina.martha.renault@regionh.dk
- Site Name
- Copenhagen University Hospital
- Department Name
- Afdeling for kvindesygdomme, graviditet og fødsler
- Contact Person Name
- Eleonora Cvetanovska
- Contact Person Email
- eleonora.cvetanovska.02@regionh.dk
Sponsor
Primary sponsor
- Full Name
- Rigshospitalet
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Denmark
Third parties
- {"country":"Denmark","full_name":"Frederiksberg Hospital","duties_or_roles":"sponsorDuties code 1","organisation_type":"Hospital/Clinic/Other health care facility"}
Investigational products
- Investigational Product Name
- Vivelle Dot 100 mikrogram/24 timer, depotplaster.
- Active Substance
- Estradiol
- Modality
- Small molecule
- Routes Of Administration
- TRANSDERMAL USE
- Route
- Transdermal
- Authorisation Status
- Marketing authorisation present (MA number 32855)
- Starting Dose
- 100 µg/24 hours
- Frequency
- Every 24 hours
- Maximum Dose
- 200 µg microgram(s)
- Investigational Product Name
- Placebo is Comfeel Plus Transparent from Coloplast. The Comfeel Plus Transparent is a thin and flexible hydrocolloid dressing. https://www.coloplast.dk/comfeel-plus-transparent-da-dk.aspx#section=product-description_3
- Modality
- Other
Related trials
Other published trials that may interest you.